Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Laboratory Investigation (Impact Factor: 3.83). 08/2011; 91(10):1427-33. DOI: 10.1038/labinvest.2011.118
Source: PubMed

ABSTRACT Nodular fasciitis (NF) is a relatively common mass-forming and self-limited subcutaneous pseudosarcomatous myofibroblastic proliferation of unknown pathogenesis. Due to its rapid growth and high mitotic activity, NF is often misdiagnosed as a sarcoma. While studying the USP6 biology in aneurysmal bone cyst and other mesenchymal tumors, we identified high expression levels of USP6 mRNA in two examples of NF. This finding led us to further examine the mechanisms underlying USP6 overexpression in these lesions. Upon subsequent investigation, genomic rearrangements of the USP6 locus were found in 92% (44 of 48) of NF. Rapid amplification of 5'-cDNA ends identified MYH9 as the translocation partner. RT-PCR and direct sequencing revealed the fusion of the MYH9 promoter region to the entire coding region of USP6. Control tumors and tissues were negative for this fusion. Xenografts of cells overexpressing USP6 in nude mice exhibited clinical and histological features similar to human NF. The identification of a sensitive and specific abnormality in NF holds the potential to be used diagnostically. Considering the self-limited nature of the lesion, NF may represent a model of 'transient neoplasia', as it is, to our knowledge, the first example of a self-limited human disease characterized by a recurrent somatic gene fusion event.


Available from: Michele Erickson-Johnson, Aug 13, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The classification of the breast tumors has been revised and recently published in 2012 in the WHO blue book. Contrary to the epithelial tumors in the breast, mesenchymal tumors are rare and the classification for benign and malignant tumors is based on the same criteria in both categories, since no other specific diagnostic criteria, which would have an impact on prognosis, exist to date. The present review deals with minor changes mirroring the recent developments in the benign mesenchymal tumors (new additions are nodular fasciitis and atypical vascular lesions, while the haemangiopericytoma is removed) focusing especially on criteria to diagnose sarcomas, which represent a wide spectrum including very difficult lesions. The majority of sarcomas of the breast arise as a component of a malignant phyllodes tumor, while the pure forms are very rare. When a pure primary sarcoma of the breast is diagnosed, pathologists are encouraged to categorize the lesion according to the type of differentiation and to provide to the clinicians all the important prognostic parameters for the best treatment choice. Copyright © 2014 Elsevier Masson SAS. All rights reserved.
    Annales de Pathologie 12/2014; 35(1). DOI:10.1016/j.annpat.2014.10.001 · 0.29 Impact Factor
  • Annales de Pathologie 12/2014; 35(1). DOI:10.1016/j.annpat.2014.11.003 · 0.29 Impact Factor
  • Annales de Pathologie 12/2014; 35(1). DOI:10.1016/j.annpat.2014.09.003 · 0.29 Impact Factor